地诺单抗是哪里产的？

It is the first approved monoclonal antibody specifically targeting RANK ligand. RANK ligand is a transmembrane or soluble protein that is necessary for osteoclasts to maintain their structure, function, and survival. The mRNA of human RANKL is mainly found in bones, bone marrow and lymphoid tissues. Its main function in bones is to stimulate the differentiation and activity of osteoclasts and inhibit the apoptosis of osteoclasts.

Denosumab is approved for the prevention of bone-related events in patients with bone metastases from solid tumors. It is not indicated for the prevention of bone-related events in patients with multiple myeloma, and for the treatment of hypercalcemia in adults or bone-mature adolescents with giant cell tumors of bone who are unresectable or surgically resectable malignancies that may cause serious complications and are bisphosphonate-resistant.

The manufacturer of denosumab is Amgen of the United States. Amgen is principally engaged in the discovery, development, production and sales of innovative drugs for human use, and is committed to exploring the potential of biotechnology for the treatment of patients with serious diseases. By leveraging cutting-edge human genetics and other tools, Amgen seeks to unravel the complexity of disease and lay the foundation for understanding human biology. 

On May 27, 2019, Amgen China announced the launch of denosumab in my country. This approval makes denosumab the first and currently the only drug for the treatment of giant cell tumor of bone, bringing patients an innovative treatment option to control disease progression and improve quality of life. 

The latest analysis of research presented at the European Society for Medical Oncology (ESMO) Annual Meeting in 2017 showed that among patients who could be surgically resected, 80% improved after receiving neoadjuvant denosumab: 44% underwent surgery with less impact on function, and 37% avoided surgery. In unresectable patients, denosumab resulted in effective long-term disease control, with a 5-year progression-free survival (PFS) rate of 88%.

Currently, the cheaper one on the market is sold by Amgen in Türkiye. The price is relatively low. Patients can consult a medical companion to purchase it.